File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3390/cancers17050890
- Scopus: eid_2-s2.0-86000490067
- WOS: WOS:001442274700001
- Find via

Supplementary
- Citations:
- Appears in Collections:
Article: LiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
| Title | LiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma |
|---|---|
| Authors | |
| Keywords | hepatocellular carcinoma intrahepatic cholangiocarcinoma metabolic dysfunction-associated steatotic liver disease/steatohepatitis |
| Issue Date | 5-Mar-2025 |
| Publisher | MDPI |
| Citation | Cancers, 2025, v. 17, n. 5 How to Cite? |
| Abstract | Background: Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two distinct types of primary liver cancer (PLC) characterized by considerable extents of cellular and molecular heterogeneities. We recently developed a web-based cell atlas called LiverSCA that possesses a user-friendly interface and comprehensive functionalities. It facilitates the exploration of gene expression patterns, cellular compositions, and intercellular communication within the microenvironments of liver and PLC tumors. Methods: To further enhance the documentation of data pinpointing different phenotypes/subtypes of liver and PLC, we extended the catalog of LiverSCA with additional datasets, e.g., ICC and metabolic dysfunction-associated steatotic liver disease/steatosis (MASLD/MASH). Results: The current enhanced version of the LiverSCA cell atlas encompasses six phenotypes (normal, HBV-HCC, HCV-HCC, non-viral HCC, ICC, and MASH), 63 patients, and over 248,000 cells. Furthermore, we have incorporated comparative visualization methods that allow users to simultaneously examine and compare gene expression levels between two different phenotypes. Conclusions: We are committed to the continuous development of LiverSCA and envision that it will serve as a valuable resource to support researchers in convenient investigations into the cellular and molecular landscapes of liver and PLC. |
| Persistent Identifier | http://hdl.handle.net/10722/357667 |
| ISSN | 2023 Impact Factor: 4.5 2023 SCImago Journal Rankings: 1.391 |
| ISI Accession Number ID |
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Suoangbaji, Tina | - |
| dc.contributor.author | Long, Renwen | - |
| dc.contributor.author | Ng, Irene Oi Lin | - |
| dc.contributor.author | Mak, Loey Lung Yi | - |
| dc.contributor.author | Ho, Daniel Wai Hung | - |
| dc.date.accessioned | 2025-07-22T03:14:11Z | - |
| dc.date.available | 2025-07-22T03:14:11Z | - |
| dc.date.issued | 2025-03-05 | - |
| dc.identifier.citation | Cancers, 2025, v. 17, n. 5 | - |
| dc.identifier.issn | 2072-6694 | - |
| dc.identifier.uri | http://hdl.handle.net/10722/357667 | - |
| dc.description.abstract | <p>Background: Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) are two distinct types of primary liver cancer (PLC) characterized by considerable extents of cellular and molecular heterogeneities. We recently developed a web-based cell atlas called LiverSCA that possesses a user-friendly interface and comprehensive functionalities. It facilitates the exploration of gene expression patterns, cellular compositions, and intercellular communication within the microenvironments of liver and PLC tumors. Methods: To further enhance the documentation of data pinpointing different phenotypes/subtypes of liver and PLC, we extended the catalog of LiverSCA with additional datasets, e.g., ICC and metabolic dysfunction-associated steatotic liver disease/steatosis (MASLD/MASH). Results: The current enhanced version of the LiverSCA cell atlas encompasses six phenotypes (normal, HBV-HCC, HCV-HCC, non-viral HCC, ICC, and MASH), 63 patients, and over 248,000 cells. Furthermore, we have incorporated comparative visualization methods that allow users to simultaneously examine and compare gene expression levels between two different phenotypes. Conclusions: We are committed to the continuous development of LiverSCA and envision that it will serve as a valuable resource to support researchers in convenient investigations into the cellular and molecular landscapes of liver and PLC.</p> | - |
| dc.language | eng | - |
| dc.publisher | MDPI | - |
| dc.relation.ispartof | Cancers | - |
| dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
| dc.subject | hepatocellular carcinoma | - |
| dc.subject | intrahepatic cholangiocarcinoma | - |
| dc.subject | metabolic dysfunction-associated steatotic liver disease/steatohepatitis | - |
| dc.title | LiverSCA 2.0: An Enhanced Comprehensive Cell Atlas for Human Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma | - |
| dc.type | Article | - |
| dc.identifier.doi | 10.3390/cancers17050890 | - |
| dc.identifier.scopus | eid_2-s2.0-86000490067 | - |
| dc.identifier.volume | 17 | - |
| dc.identifier.issue | 5 | - |
| dc.identifier.eissn | 2072-6694 | - |
| dc.identifier.isi | WOS:001442274700001 | - |
| dc.identifier.issnl | 2072-6694 | - |
